Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL6030 Target Snapshot

Eukaryotic translation initiation factor 2-alpha kinase 3 · SINGLE PROTEIN · Homo sapiens

473Compounds
147Assays
0Approved Drugs
616.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Protein identity stays anchored to UniProt Q9NZJ5. Use UniProt Q9NZJ5 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt Q9NZJ5 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Eukaryotic translation initiation factor 2-alpha kinase 3 as ChEMBL target CHEMBL6030, mapped to UniProt Q9NZJ5. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Eukaryotic translation initiation factor 2-alpha kinase 3
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL6030
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
Q9NZJ5
Eukaryotic translation initiation factor 2-alpha kinase 3
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Eukaryotic translation initiation factor 2-alpha kinase 3 is the right protein anchor across sources, using UniProt Q9NZJ5 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelEukaryotic translation initiation factor 2-alpha kinase 3
UniProt AccessionQ9NZJ5
Component TypeProtein
Sequence Length1116 aa

Eukaryotic translation initiation factor 2-alpha kinase 3

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Eukaryotic translation initiation factor 2-alpha kinase 3, mapped to UniProt Q9NZJ5. Sequence length is 1116 aa.

Mapped IDQ9NZJ5
Review nameEukaryotic translation initiation factor 2-alpha kinase 3
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

1
Phase I
Assay Mix

Activity Type Distribution

IC50349.0
EC50267.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL2171122 9.7 IC50 0.2 Preclinical
CHEMBL2171126 9.7 IC50 0.2 Preclinical
CHEMBL2171141 9.7 IC50 0.2 Preclinical
CHEMBL2171143 9.7 IC50 0.2 Preclinical
CHEMBL2171144 9.7 IC50 0.2 Preclinical
CHEMBL2171125 9.52 IC50 0.3 Preclinical
CHEMBL2171124 9.4 IC50 0.4 Preclinical
CHEMBL2171139 9.4 IC50 0.4 Preclinical
CHEMBL3355039 9.4 IC50 0.3981 Preclinical
CHEMBL2171123 9.3 IC50 0.5 Preclinical
Distribution

pChEMBL Value Distribution

17
5.0
21
5.5
30
6.0
45
6.5
66
7.0
35
7.5
27
8.0
17
8.5
17
9.0
6
9.5
pChEMBL
Assay Landscape

Assay Landscape

147
Total Assays
223
Tested Compounds
2
Assay Types
Binding — 145 assays, 223 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 95 126 7.5
cell-based format 33 48 6.6
subcellular format 12 0
assay format 5 49 7.8
Functional — 2 assays, 1 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 2 1 4.6

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine